ADPT
Adaptive Biotechnologies Corporation
Diagnostics & Research · Healthcare · United States
26.64
close · 2026-10-30
value
9
cheaper than peers9
quality
11
stronger fundamentals11
ranked against
Diagnostics & Research
value
quality
31 peers
Value inputs
| measure | company | vs peers |
| earnings yield, 3 years ago | -5.3% | 35 |
| earnings yield, latest year | -1.5% | 34 |
| earnings yield, 2 years ago | -5.9% | 31 |
| cash flow yield, 2 years ago | -3.9% | 27 |
| earnings yield, 1 year ago | -4.1% | 27 |
| cash flow yield, 3 years ago | -4.7% | 27 |
| cash flow yield, latest year | -1.2% | 24 |
| cash flow yield, 1 year ago | -2.3% | 24 |
| price to sales | 13.80× | 18 |
| price to book | 29.67× | 9 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| revenue growth | 21.5% | 73 |
| operating margin | -22.0% | 22 |
| return on equity | -38.8% | 12 |
| debt to equity | 272.5% | 5 |
4 of 4 measures available
Facts
| market cap | $4B |
| free cash flow | $16.1M |
| employees | 624 |
| first trade | 2019-06-27 |
| next earnings | 2026-11-04 |
| fundamentals updated | 2026-08-05 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -0.39 | -1.08 | -1.56 | -1.40 |
| free cash flow | -$48.9M | -$98.9M | -$167.0M | -$200.3M |
| net income | -$59.5M | -$159.5M | -$225.3M | -$200.2M |
| revenue | $277.0M | $179.0M | $170.3M | $185.3M |
| unusual items | $0 | -$7.2M | -$25.4M | $0 |